Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies.
Clotrimazole (Bay b 5097) is a new synthetic antifungal drug with in vitro activity against Candida spp., Torulopsis glabrata, and Saccharomyces spp. Pharmacological studies in man after the oral administration of 1.5 and 3 g of clotrimazole produced mean peak concentrations in the serum of 1.16 and 1.29 mug/ml, respectively, 2 hr after administration. In six patients taking 1.5 g of clotrimazole every 6 hr, there was a progressive decline in the serum concentrations after administration of a dose on days 1, 4, and 8. Nine other patients begun on a similar schedule manifested gastrointestinal symptoms attributed to the clotrimazole and were unable to complete the study. Concentrations of active drug in the urine were less than 1% of the administered dose.
D000935:Antifungal Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D002175:Candida / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D009181:Mycoses / Q000517:prevention & control; D012440:Saccharomyces / Q000187:drug effects; D014320:Triphenylmethyl Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D000935:Antifungal Agents; D007093:Imidazoles; D014320:Triphenylmethyl Compounds